$DOO

BRP (TSE:DOO) Stock Price Expected to Rise, Desjardins Analyst Says

Desjardins raised its BRP (TSE:DOO) price target to C$103 from C$97 and kept a “buy” rating, implying 27.95% upside versus the prior close, according to BayStreet.CA. Other analysts adjusted targets: Scotiabank to C$83, National Bank to C$84, BMO to C$120, Canaccord cut to C$90, and Raymond James to “market perform.” BRP shares rose to C$80.50.

Original reporting
Published Jun 1, 2026, 7:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 1, 2026, 7:51 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
BRP (TSE:DOO) Stock Price Expected to Rise, Desjardins Analyst Says — source image
Decision brief

The 30-second read

$DOOBullishMed
01

Why it matters

Raised targets can attract incremental buyers, but without new company fundamentals (no new guidance/earnings in this piece) the move may fade if broader market risk-off emerges.

02

Market read

Near-term trading bias is bullish due to a raised target and “buy” rating, tempered by mixed calls from other brokerages.

03

What to watch

High leverage metrics (debt-to-equity 419.45) and weak liquidity ratios (quick ratio 0.20) could cap rallies even if targets rise.

Relevance 7/10Novelty 6/10Timing: today/next session after the analyst note and midday trading update

Background

The article summarizes a fresh analyst note from Desjardins plus other recent target changes, and includes basic trading/valuation and the last reported quarter’s EPS/revenue.

Company-level read

Ticker impact

$DOOBullishMedium confidence
Context

Desjardins raised BRP’s price target to C$103 and kept a “buy” rating, implying ~28% upside from the prior close.

Expected impact

Mild-to-moderate upside bias over days/weeks; follow-through depends on whether price can sustain above near-term moving averages.

Evidence & confidence

The only new actionable item is the raised target/rating; no new earnings or guidance is reported in the article beyond referencing the prior May 28 results.

Market effects

Positive read-through for powersports/rec vehicles sentiment if analysts are broadly revising targets upward.

Primarily Canada-listed BRP sentiment; limited spillover beyond North American retail/investor flows.

Low global macro relevance; mostly company-specific analyst positioning.

Counterpoint

Several analysts also downgraded BRP (e.g., Canaccord to hold; Raymond James to market perform), suggesting the upside case is not unanimous.

Key entities

  • BRP

    Powersports manufacturer; subject of the analyst target raise and the trading/valuation snapshot in the article.

  • Desjardins

    Raised BRP’s price target from C$97 to C$103 and maintained a “buy” rating.

Related articles

$DOOMed

Wednesday’s analyst upgrades and downgrades

TD Cowen upgraded BRP Inc. (DOO) to 'buy' citing strong demand for side-by-side vehicles and potential tariff exposure reduction. Analyst Brian Morrison raised the target price to $106 and forecasts 6% revenue growth. Air Canada (AC) received a target price increase to $38 from Stifel's Daryl Young following a $2.5B Aeroplan stake sale and strong Q2 results. Scotia's Konark Gupta also raised his target to $37.50. Cadillac Mines (CADY) received an 'outperform' rating from National Bank's Don DeMa

$DOOMedAI 9/10

BRP Reports Lower Q1 Profit Over Unfavorable Foreign Exchange Rate, Stock Up

BRP Inc. reported first-quarter profit for the period ended April 30, 2026 fell to C$127.3 million from C$161.0 million in 2025, citing unfavorable FX on U.S.-denominated long-term debt and higher income taxes, partially offset by higher operating income. Revenue rose to C$2,391.8 million. EPS was C$1.73 vs C$2.19. Normalized net income and EPS increased; 2027 guidance: EPS C$3.00–C$3.50, normalized EBITDA C$925–C$975 million, net income C$215–C$250 million. Shares rose on the day.

$PDDMedAI 8/10

Housing, Employment Numbers Featured in Short Week in U.S.

The article previews a short U.S. and Canada market week after Memorial Day, highlighting housing, confidence, jobs, and earnings. It lists U.S. EPS results for PDD, AutoZone, Elbit, Salesforce, Synopsys, Marvell, Costco, Dell, and Autodesk, plus Canada banks’ and other firms’ EPS. Key data include S&P Case-Shiller (March), jobless claims and durable goods (May 23/April), and Canada payroll employment and GDP.

$MRKHighAI 9/10

StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too

Merck (MRK) and Moderna (MRNA) announced positive Phase III results for their cancer vaccine, intismeran, showing improved outcomes when combined with Keytruda. Shares of both companies surged, with Moderna gaining 130.5% over three days. Sequencing companies like Illumina (ILMN) and PacBio (PACB) also saw gains due to the personalized nature of the therapy. Analysts upgraded Moderna's stock, citing broadened sales potential, while others remained cautious about long-term expectations.

$BAMedAI 8/10

Boeing’s MAX 10 Schedule Puts 27 United Planes Beyond 2027 as Labor Tensions Rise

Boeing's MAX 10 delays push 27 United Airlines jets to post-2027 delivery, per United's latest filing. Boeing completed flight tests but awaits certification. BA shares fell 7.5% last week, erasing $13.8B in market cap. Labor tensions rise as Boeing engineers reject contract offers, risking a strike. Boeing's Q2 revenue rose 8% to $24.56B, with a $715B backlog. Analysts maintain a positive outlook, with a consensus price target of $274.85.

$TEVAMed

Teva share price hits nearly 10-year high

Teva Pharmaceutical (TEVA) reached a nearly 10-year high, with shares up 1.44% on Friday, giving a $43.51B market cap. The company reported strong Q2 results, raised annual revenue guidance, and received debt rating upgrades from Moody's and Fitch. The FDA accepted its Ecopipam drug application. Analysts have an average price target of $42.38, a 12.3% premium to current levels.